pulmo trackselling in europe china and taiwan, page-7

Eyeknow, I share your view on KSX longterm. Their technology is a seller and they obviously have the right people with the right amount of $$ behind it.

Regulatory approvals in China though take 12months and they DON'T have them in place. So why would they want to risk having a similar competing product (maybe not by 'reverse engineering') being developed that is just as accurate at half the cost with twice as much GP.

Any future potential high net worth investors/groups will take that into account before investing imo.

That risk alone must now be re-priced.

The potential massive size of this market requires KSX director's to be a little more conservative in the commercialisation process of its products imo.

Perhaps they understand the risk and are fishing out the likely culprits first.

Only time will tell.